Advertisement


Drug Controller General Of India Dcgi
India  /  Published 13.08.21

DCGI nod for nasal vaccine trials

The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday. P...
By Our Bureau, PTI in Hyderabad

India  /  Published 01.07.21

Covid: Sputnik-Light fails to get nod

 India's drug regulator has refused to grant emergency-use authorisation to single-dose COVID-19 vaccine Sputnik-Light, while ruling out the need for the conduct of the phase-3 trial of the R...
By Our Bureau, PTI in New Delhi

India  /  Published 22.06.21

Covaxin: 77.8% efficient in trials

An expert panel of the country's central drugs authority has reviewed and accepted the phase-3 trial data of Bharat Biotech's COVID-19 vaccine Covaxin, sources said on Tuesday. According to t...
By Our Bureau in New Delhi

India  /  Published 03.06.21

SII seeks nod to make Sputnik V in India

The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufacture Covid-19 vaccine Sputnik V in the country, sources said on Thursday. Th...
By Our Bureau, Agencies in Hyderabad

India  /  Published 02.06.21

DCGI move to bolster foreign jab supply

India's apex drug regulator has waived the requirement of testing every batch of foreign-made Covid-19 vaccines by the Central Drugs Laboratory, Kasauli and post-launch bridging trials for such fi...
By Our Bureau, Agencies in New Delhi

Advertisement

India  /  Published 08.05.21

DCGI nod to DRDO Covid drug

  An anti-COVID oral drug developed by the DRDO has been approved by the Drugs Controller General of India (DCGI) for emergency use as an adjunct therapy in moderate to severe coronavirus patien...
By Our Bureau, Agencies in New Delhi

India  /  Published 23.04.21

DCGI nod to Zydus Covid drug

Drug firm Zydus Cadila on Friday said it has received restricted emergency use approval from the Indian drug regulator for the use of Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-...
By Our Bureau, Agencies in New Delhi

Jharkhand  /  Published 03.01.21

Co-Win: need for more sessions

Sources in the health department said they were expecting to start vaccinations for the first phase from the second week of January. “We will get a formal intimation. But we think the vaccines w...
By Our Correspondent in Ranchi

India  /  Published 03.01.21

Cong: why skip phase 3 trials?

Moments after the Drugs Controller General of India granted permission for the restricted emergency use of two vaccines in the country on Sunday, senior Congress leader Anand Sharma raised concern ove...
By Our Bureau, Agencies in New Delhi

India  /  Published 03.01.21

Emergency use nod for two vaccines in India

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of...
By Our Bureau, Agencies in New Delhi


Advertisement

Download our latest App

to get update on the go...

Advertisement

Advertisement
 
Copyright © 2020 The Telegraph. All rights reserved.